YOUR GO-TO INTELLIGENCE RESOURCE FOR THE SCHOLARLY PUBLISHING INDUSTRY

Elsevier has introduced PharmaPendium AI, a generative AI solution built to streamline access to regulatory insights across the drug development lifecycle. The solution is layered over PharmaPendium, Elsevier’s core regulatory tool, and leverages AI to support professionals working in regulatory affairs, preclinical, and clinical research domains who deal with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulatory documents

The solution applies retrieval augmented generation (RAG) and natural language processing (NLP) to surface citation-backed responses drawn exclusively from a structured body of over 5 million pages of U.S. FDA and EMA documents, including approval packages, transcripts, and reference texts such as Meyler’s Side Effects of Drugs.

Users can pose natural language queries and receive structured responses aligned to regulatory language and submission formats. These outputs include submission-ready tables and summaries with embedded citations, improving both speed and regulatory-grade reliability. According to early feedback, some teams have reported up to 66% time savings per search and review session.

Key features of PharmaPendium AI include:

• Search support across multiple languages to foster cross-border collaboration.

• A controlled environment that avoids AI hallucinations by restricting data generation strictly to PharmaPendium content.

• Expert oversight mechanisms to validate prompt design and output quality.

• Secure architecture that ensures privacy and does not reuse user data for model training, working in accordance with Elsevier’s Responsible AI Principles and Privacy Principles.

The solution reflects Elsevier’s stated focus on enabling pharmaceutical R&D with responsible AI integration and complements a suite of AI-enabled tools aimed at enhancing innovation and efficiency across the sector.